Gotowe bibliografie tematyczne / Colorectal cancer

Gotowa bibliografia na temat „Colorectal cancer”

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 31 sierpnia 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Artykuły w czasopismach
Rozprawy doktorskie
Książki
Części książek
Streszczenia konferencji
Raporty organizacyjne

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Colorectal cancer”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Colorectal cancer"

DA SILVA, FELIPE CARNEIRO, PATRIK WERNHOFF, CONSTANTINO DOMINGUEZ-BARRERA i MEV DOMINGUEZ-VALENTIN. "Update on Hereditary Colorectal Cancer". Anticancer Research 36, nr 9 (9.09.2016): 4399–406. http://dx.doi.org/10.21873/anticanres.10983.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Chandio, Ashfaq. "Can we predict colorectal cancer?" Clinical Medical Reviews and Reports 3, nr 2 (17.03.2021): 01–07. http://dx.doi.org/10.31579/2690-8794/065.

Pełny tekst źródła

Streszczenie:

Background: Colorectal cancer is a common and lethal cancer worldwide, In the UK, it is the second most common cause of cancer death. 5% of UK population is at risk of colorectal carcinoma during lifetime. 30% of patients with colorectal cancer present with a metastatic disease. Detecting colorectal cancer is challenging patients may present with slight symptoms or asymptomatic. By the time patients becomes symptomatic, the cancer may be more advanced. Therefore, screening for colorectal cancer is recommended for people at average risk. Method: All patients diagnosed with colorectal cancer at the Luton and Dunstable University Hospital UK from January 2015 through December 2019 were retrospectively identified from the referral database created by colorectal specialist nurses in the colorectal service. Data were retrieved by detailed review of the hospital case notes, ICE/Evolve (Computer database for investigations and correspondence) including endoscopy; radiographic imaging; operative course and cancer follow up. Results: In the study period 976 patients were diagnosed with colorectal cancer, Male 52.6% (513) Female 47.4% (463). The mean age of 74.14 years (range, 25 to 101). Sixty six 6.76% patients were excluded from the study, therefore the percentages of studied participant were Male 53 % (482) and Female 47 % (428) ratio 1: 1.12. Incidence of colorectal cancer among young adult was low 1.75% (16) up to 39 years of age) and 94.61% are diagnosed in people over the age of 50 years, 60.43% are diagnosed in people aged 70 or over. Conclusion: Increasing awareness of the symptoms and signs of colorectal cancer be helpful and beneficial. Establish integrated care pathways, centralization of complex procedures and comparison of international cancer outcomes.

Style APA, Harvard, Vancouver, ISO itp.

Wang, Ning, Yang Chen, Yuchen Han, Yue Zhao, Yu Liu, Kejian Guo i Yi Jiang. "Proteomic analysis shows down-regulations of cytoplasmic carbonic anhydrases, CAI and CAII, are early events of colorectal carcinogenesis but are not correlated with lymph node metastasis". Tumori Journal 98, nr 6 (listopad 2012): 783–91. http://dx.doi.org/10.1177/030089161209800617.

Pełny tekst źródła

Streszczenie:

Aim The aim of the study was to screen the markedly down-regulated proteins in colorectal cancer and analyze their relationship to carcinogenesis, cancer progression and pathological aspects. Methods Proteomic analysis was preformed on six fresh colorectal cancer tissues and paired normal colorectal mucosa by two-dimensional differential gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Two markedly down-regulated proteins among the proteins, of which the expressions were significantly decreased in colorectal cancer compared to normal mucosa, were confirmed by Western Blot in 12 colorectal cancers. Their relationship to carcinogenesis, cancer progression and pathological aspects of colorectal cancer were analyzed in 64 colorectal cancer and paired normal mucosa, 27 benign polyps, and 20 lymph node metastases by immunohistochemistry. Results Two-dimensional differential gel electrophoresis analysis showed there were 2 protein spots, of which the average abundances decreased 3.62 and 3.76 fold in colorectal cancer compared to normal mucosa, respectively. They were identified by matrix-assisted laser desorption/ionization-time of flight mass spectrometry as carbonic anhydrase I and II (CAI and CAII). Validation by Western Blot in 12 colorectal cancers showed there were significantly different expressions of CAI and CAII between colorectal cancer and normal mucosa (P = 0.002 and 0.027, respectively). Immunohistochemistry analysis indicated the expression of CAI and CAII was decreased from normal mucosa to benign polyps, and to colorectal cancer stepwise significantly (P <0.05). However, there were no differences in their expressions between lymph node metastasis and colorectal cancer (P >0.05). There were decreasing trends of CAI and CAII expressions from well to poor differentiation and from stage I or II to stage III or IV, but they were not statistically significant (P >0.05). Conclusions CAI and CAII are necessary enzymes of the colorectum for their normal function. Down-regulations of CAI and CAII are early events of colorectum carcinogenesis. They have no correlations with lymph node metastasis.

Style APA, Harvard, Vancouver, ISO itp.

Tripathi, Tanya, A. N. Srivastava i Sharique Ahmad. "MICROSATELLITE INSTABILITY : CORELATION WITH COLORECTAL CANCER". Era's Journal of Medical Research 6, nr 2 (grudzień 2019): 139–46. http://dx.doi.org/10.24041/ejmr2019.144.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

S., Anitha, Sridevi P. i Durga K. "Role of p53 Mutations in Colorectal Cancer". Indian Journal of Pathology: Research and Practice 6, nr 1 (2017): 105–10. http://dx.doi.org/10.21088/ijprp.2278.148x.6117.17.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Ishaq, Aliya. "Age Related Disparities in Colorectal Cancer Patients". Journal of Clinical and Laboratory Research 3, nr 3 (11.09.2021): 01–04. http://dx.doi.org/10.31579/2768-0487/064.

Pełny tekst źródła

Streszczenie:

Background: There is an evident change in the colorectal cancer demographic over the period. This change is more marked in the age distribution and location of the tumor. It has practical implications, in regards to develop cancer awareness programs and screening protocols. Keeping in view that Pakistan is one of the countries with a high number of the young population this study is carried out to make a comparative analysis of this trend in our population. Material and methods: Colorectal cancer patients presented in Sindh Institute of urology and transplantation from January 2011 till December 2020 was reviewed retrospectively. All patients were divided into two groups, Group A young age population and Group B old age population. Subgroup analysis of study period was performed to check the progressive change in the trend of stage and clinical characteristics of colorectal cancer patients. Data reviewed from the patient’s files and collected as per Proforma requirement. Result: Total of 612 patients with colorectal cancer presented between 2011 till 2020.Among these patients 243 (39.7%) presented between January 2011 till December 2015. Patients age 50 years and younger were 410 (66.8%). Results showed a statistically significant association between and patient’s age and location of tumor such that left-sided colonic cancer and rectal cancer were more common in the young population. Subgroup analysis according to the study period showed that there is a change in the trend of disease presentation. Right-sided colonic cancer presentation decreased in the younger population over the period while simultaneously left-sided colonic cancer and rectal cancer presentation increased. Conclusion: The incidence of left-sided colonic and rectal cancer has been increased in the younger population over the specified period while there was no association between right-sided colon cancer and age noticed.

Style APA, Harvard, Vancouver, ISO itp.

Chandio, Ashfaq, Anil Rai, Mehak Chandio, Asirvatham Rhody i Katherine Brown. "Outcome of Colorectal cancer in Geriatric Patient". Cancer Research and Cellular Therapeutics 5, nr 4 (30.08.2021): 01–07. http://dx.doi.org/10.31579/2640-1053/094.

Pełny tekst źródła

Streszczenie:

Background: Older surgical patients remain at increased risk of adverse postoperative outcome when undergoing both elective and emergency surgery. The needs of the older surgical patient are often substantially different from those of younger patients. As a surgeons we have dilemmas in appropriately treating elderly patients. Specifically, those with cancer have been shown to receive inappropriate care, being either undertreated or overtreated based on their chronological age rather than their degree of frailty. Aim:To evaluate outcome of patients diagnosed with colorectal cancer in patients aged 80 years and over. Methods:Retrospective study of all patients 80 years and above managed with colorectal cancer at the Luton and Dunstable University Hospital UK from January 2015 through December 2019 Results: In the study period 278 patients were diagnosed with colorectal cancer, Male 143 Female 135 ratio 1:1.05. Age range from 80 to 101years. 54.31% patients underwent surgical intervention. 15.10% had complications after surgery. 36.69% patients deemed unsuitable for resection surgery were treated with best supportive care palliatively. 57.19% patients were in ASAIII, 24.10% ASAII and 12.23% ASAIV. 46.40% patients died during the study period. Conclusion:Age on its own would not be taken as for less aggressive therapy; Careful assessment of the patient taking into consideration comorbidities, functional status and patient wishes are essential in decision making and choosing appropriate management plan. Curative surgery for colorectal carcinoma in the geriatric patients are well tolerated. Management of comorbidities preceding surgery may impact postoperative outcome.

Style APA, Harvard, Vancouver, ISO itp.

Magar, Chin Bahadur Pun, Ranjan Raj Bhatta, Greta Pandey, Suraj Uprety, Ishan Dhungana i Nandita Jha. "An Overview of Colorectal Cancer in Tertiary care Cancer Center of Nepal". Nepalese Journal of Cancer 6, nr 2 (6.10.2022): 40–45. http://dx.doi.org/10.3126/njc.v6i2.48766.

Pełny tekst źródła

Streszczenie:

Introduction: Colorectal carcinoma is primary epithelial malignancy arising in the colorectum areas. 98% of colonic and rectum cancers are adenocarcinomas. The prevalence of colorectal cancer has been dramatically growing at an alarming rate globally in recent years. Materials and methods: This is retrospective study at Department of Pathology in B P Koirala Memorial Cancer Hospital effective from 1st January 2018 to 31st December 2019. All the data were retrieved and analyzed. Results:Total 56 colorectal cancer cases were analyzed, among them 36 cases were males accounting 64 % and 20 cases were females accounting 36 %. Rectum was the commonest site and commonest age group was 61-70 years accounting 55.3%. 44.6% cases were in advanced stage either stage III or IV. Conclusion:Colorectal cancer is more common in males than in females. Most commonly affected age group was 61-70 years. Most common histological type was well differentiated adenocarcinoma. 44.6% cases were diagnosed in advanced stage either stage III or IV.

Style APA, Harvard, Vancouver, ISO itp.

Ma, Yu-Shui, Wen Li, Yu Liu, Yi Shi, Qin-Lu Lin i Da Fu. "Targeting Colorectal Cancer Stem Cells as an Effective Treatment for Colorectal Cancer". Technology in Cancer Research & Treatment 19 (1.01.2020): 153303381989226. http://dx.doi.org/10.1177/1533033819892261.

Pełny tekst źródła

Streszczenie:

As one of the common cancers that threaten human life, the recurrence and metastasis of colorectal cancer seriously affect the prognosis of patients. Although new drugs and comprehensive treatments have been adopted, the current treatment effect on this tumor, especially in advanced colorectal cancer, is still not satisfactory. More and more evidence shows that tumors are likely to be a stem cell disease. In recent years, the rise of cancer stem cell theory has provided a new way for cancer treatment. Studies have found that a small number of special cells in colorectal cancer tissues that induce tumorigenesis, proliferation, and promote tumor migration and metastasis, namely, colorectal cancer stem cells. Colorectal cancer stem cells are defined with a group of cell-surface markers, such as CD44, CD133, CD24, epithelial cell adhesion factor molecule, LGR5, and acetaldehyde dehydrogenase. They are highly tumorigenic, aggressive, and chemoresistant and thus are critical in the metastasis and recurrence of colorectal cancer. Therefore, targeting colorectal cancer stem cells may become an important research direction for the future cure of colorectal cancer.

Style APA, Harvard, Vancouver, ISO itp.

Hong, Seung Wook, i Jeong-Sik Byeon. "Endoscopic diagnosis and treatment of early colorectal cancer". Intestinal Research 20, nr 3 (30.07.2022): 281–90. http://dx.doi.org/10.5217/ir.2021.00169.

Pełny tekst źródła

Streszczenie:

Early colorectal cancer refers to cancer in the colorectum that is confined to the mucosa or submucosa and does not invade the muscularis propria, irrespective of lymph node or distant metastasis. As the number of persons undergoing screening colonoscopy increases, the proportion of patients diagnosed with precancerous colorectal lesions and early colorectal cancer also increases. In the last decade, innovative optical technologies for endoscopic diagnosis have been introduced and endoscopic treatment techniques such as endoscopic submucosal dissection have provided major breakthroughs in the management of early colorectal cancer. With these remarkable developments, endoscopic treatment has established itself as an alternative to surgical resection in the treatment of early colorectal cancer. This review will discuss the endoscopic diagnosis and treatment of early colorectal cancer. Furthermore, the unmet needs in this field and the latest research addressing those issues will be summarized.

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Rozprawy doktorskie na temat "Colorectal cancer"

Pfeifer, Daniella. "p73 in colorectal cancer". Doctoral thesis, Linköpings universitet, Onkologi, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-18432.

Pełny tekst źródła

Streszczenie:

Colorectal cancer (CRC) is the third most common cancer in the world, with about 5000 new cases in Sweden every year. CRC is caused by mutation (inherited or acquired) in genes, by gene variants and changed expression of proteins. The primary way to achieve a curative result for CRC is to remove the tumor by surgery. To reduce risk of recurrence chemo- or radiotherapy are given as a complement to surgery. p73 is a structural and functional homologue of tumor suppressor p53. However, p73 is rarely mutated in tumors, but rather overexpressed as compared to normal tissue. There are two main isoforms of p73, the transactivation capable TAp73 and the truncated ΔNp73, which are involved in an autoregulatory loop with TAp73 and p53. The aim of this study was to investigate the role of p73 and related proteins in the development and treatment of CRC. A G4C14-to-A4T14 polymorphism of p73 was studied in CRC patients and healthy controls (Paper I), and rectal cancer patients who were randomized to treatment with either surgery alone or preoperative radiotherapy and surgery (Paper II). The AT/AT genotype of the p73 polymorphism may increase risk of CRC development and CRC patients with the AT allele had a better prognosis. When dividing the cases into colon and rectal cancer it was seen that in colon cancer the AT allele tended to be more favorable for overall survival, while in rectal cancer the GC allele seemed to be more favorable. Rectal cancer patients, with a combination of GC/GC genotype, wild type p53 and weak survivin expression survived longer after preoperative radiotherapy. This was not observed in the patients only receiving surgery. The protein expression of p73 was further studied in the rectal cancer patients randomized to treatment with either surgery alone or preoperative radiotherapy and surgery (Paper III). p73 was expressed higher in tumor tissue than in normal mucosa. Patients with p73 negative tumors had a lower risk of local recurrence after radiotherapy, as opposed to patients that had p73 positive tumors or patients with p73 negative tumors that did not receive radiotherapy. Effects of γ-radiation was further studied in colon cancer cell lines KM12C, KM12SM and KM12L4a regarding cell cycle, survival fraction (clonogenicity), apoptosis and protein expression patterns of mutated p53, TAp73, ΔNp73, survivin and PRL-3 (Paper IV). KM12C displayed low survival fraction, low apoptosis, no cell cycle arrest and an upregulation of the antiapoptotic ΔNp73 after irradiation. KM12L4a showed a high survival fraction, but high apoptosis, arresting of the cell cycle and upregulation of the radio-resistance factor survivin. The effects of overexpression and knockdown of survivin on TAp73, ΔNp73 and p53 expression in colon cancer cell lines HCT-116p53+/+ and HCT-116p53-/- with and without γ-radiation were studied (Paper V). Overexpression of survivin decreased wild type p53, whilst downregulation of survivin lead to a simultaneous downregulation of TAp73 and ΔNp73, mRNA and protein, both with and without γ- radiation. Knockdown of survivin also demonstrated an increase in apoptosis. In conclusion, we showed that the G4C14-to-A4T14 polymorphism of p73 and p73 protein expression may be involved in CRC development, radiotherapy response and survival. We further showed that TAp73, ΔNp73 and p53 were regulated by survivin in colon cancer cells.
Cancer i tjocktarmen (kolon) och ändtarmen (rectum) är den tredje vanligaste cancerformen i världen och i Sverige drabbas varje år ca 5000 personer av tjockoch ändtarmscancer. Antalet drabbade individer är högre i de industrialiserade länderna än övriga världen, vilket tyder på att vissa omgivnings- och livsstilsfaktorer påverkar risken för tjock- och ändtarmscancer. Även vissa genetiska faktorer påverkar risken för insjuknande i dessa cancerformer. En gen är mallen för ett eller flera proteiner och en förändring (mutation) i en gen kan innebära att motsvarande protein förändrar eller förlorar sin normala funktion. En del gener har också nedärvda naturliga variationer, så kallade polymorfier, vilka i sin tur kan leda till variation i funktionen hos motsvarande protein. Proteiner som förändrat eller förlorat sin normala funktion bidrar till de speciella egenskaper som finns hos cancerceller. Cancerceller till skillnad från normala celler delar sig okontrollerat, är motståndskraftiga mot den programmerade celldöd (apoptos) som normalt förstör skadade celler och kan sprida sig via blodbanan till andra organ (metastasera). Tjock- och ändtarmscancer behandlas främst med kirurgi, cellgifter och strålning och tack vare förbättrade behandlingar har dödligheten minskat de senaste årtiondena. Genom att studera olika genetiska varianter, proteiner och förhållandet mellan proteiner i cancerceller får vi större insikt i vilka faktorer som ökar risken för tjock- och ändtarmscancer, men också vilka faktorer som påverkar hur effektiv en behandling är för varje individuell patient. Målet med denna avhandling var att studera proteinet p73 och hur den påverkar risken för tjock- och ändtarmscancer och behandlingseffekten av sjukdomen. p73 tillhör samma proteinfamilj som “genomets väktare” p53 och båda har förmågan att skydda cellen genom att stoppa celldelning och inducera apoptos i skadade celler. Dock är p53 muterat i ungefär 50 % av alla tjock- och ändtarmscancrar. Genom att studera en polymorfi i p73 hos tjock- och ändtarmscancerpatienter och friska blodgivare såg vi att de individer som har dubbel uppsättning av variantgenen har ökad risk att utveckla tjock- och ändtarmscancer och att de patienter som är bärare av variantgenen hade en längre överlevnad (Paper I). Ändtarmscancerpatienter som fått strålbehandling överlevde längre om de hade dubbel uppsättning av den ursprungliga p73-genen, icke-muterat p53 och lågt uttryck (mängd) av survivin. Survivin är ett protein som normalt hindrar cancerceller från att dö (Paper II). De ändtarmscancerpatienter som behandlats med strålning och som hade p73 negativa tumörer fick mycket färre återfall än de patienter som hade p73 negativa tumörer men inte fått strålbehandling, eller som hade p73 positiva tumörer (Paper III). För att närmare studera tjocktarmscancercellers motståndsmekanismer mot strålbehandling mättes bland annat olika typer av celldöd och uttrycket av två olika varianter av p73, kallade TAp73 och ΔNp73, survivin och PRL-3. PRL-3 är ett protein som uttrycks starkast i metastatiska tumörer och leder till ökat motstånd mot strålbehandling. Den cellinje som inte dog genom apoptos hade högt uttryck av ΔNp73, vilket är en variant av p73 som hindrar celler från att dö, medan den som trots strålning i hög grad fortsatte dela sig hade ett högt uttryck av survivin (Paper IV). Efter indikationer om att uttrycket av p73 proteinerna TAp73 och ΔNp73 är kopplade till survivin undersöktes ett eventuellt förhållande mellan dessa proteiner i tjocktarmscancerceller. I de fall där uttrycket av survivin minskades i cellerna minskade också uttrycket av TAp73 och ΔNp73. Detta fenomen sågs även i celler som behandlats med strålning. En minskning av survivin i cellerna ledde även till att fler celler dog genom apoptos (Paper V). Sammanfattningsvis pekar våra resultat på att p73 spelar en viss roll i utvecklingen av tjock- och ändtarmscancer, men också avseende effekterna på strålbehandling av ändtarmscancer. Vi har också visat att TAp73, ΔNp73 och p53 regleras av survivin.

Style APA, Harvard, Vancouver, ISO itp.

Benhaim, Léonor. "Pharmacogenetics and colorectal cancer". Thesis, Paris 5, 2013. http://www.theses.fr/2013PA05P634.

Pełny tekst źródła

Streszczenie:

Le champ de la pharmacogénétique est d'une importance cruciale en oncologie pour optimiser la sélection du traitement à utiliser en fonction du profil génomique du patient et de la tumeur. En effet, au-delà des caractéristiques spécifiques de la tumeur, le génome de l'individu explique une grande partie de la variation de la réponse du observée à des agents chimiothérapeutiques à la fois en terme d'efficacité et de toxicité. Les patients atteints de cancer colorectal (CCR) sont susceptibles de recevoir une ou plusieurs lignes de chimiothérapie avec une efficacité variable et de faire l'expérience des effets secondaires connexes. Il est donc essentiel d'optimiser l’arsenal thérapeutique pour améliorer l’efficacité des traitements en évitant au maximum les effets indésirables. Le but des études de pharmacogénétique est d'étudier spécifiquement pour chaque médicament les voies métaboliques impliquées et leurs variations interindividuelles potentielles secondaires à des mutations génomiques ou somatiques. Cette recherche vise ainsi à identifier les biomarqueurs pronostiques et prédictifs qui aideront à une meilleure sélection de traitement. Pour les patients atteints de CRC, le bénéfice de survie de l'administration de la chimiothérapie adjuvante chez les patients de stade II et III reste à évaluer. En effet, l'avantage de survie donné par la perfusion de 5-fluorouracile en adjuvant (avec ou sans oxaliplatine) a été montré pour les patients de stade III CRC mais est encore indéterminé pour les patients de stade II CRC. Par définition, les mutations somatiques sont détectées dans le génome des cellules tumorales et ont été associées à la réponse aux agents chimiothérapeutiques. En outre, plusieurs rapports ont suggéré l'importance du rôle des variations héréditaires (génome constitutionnel) pour la réponse aux médicaments et à la prévision des effets secondaires. Dans ce travail, je me suis concentrée sur la relation entre les polymorphismes et la réponse aux chimiothérapies chez les patients de stade II - III CRC. J'ai observé que la cycline D1 (CCND1), les canaux sodique voltage-dépendants (SCN1A), les régulateurs de la voie WNT / β - caténine, KSR et les gènes de cellules souches cancéreuses pouvaient prédire la réponse et la survie de patients traités pour CCR en situation adjuvante
The pharmacogenetics field is of crucial importance in oncology to optimize the selection of which chemotherapy regimen to use according to the patient’s and tumor’s genomic profile. Indeed, beyond the specific tumor characteristics, the individual’s inherited genome accounts for a large proportion of the variation in patient’s response to chemotherapeutic agents both in term of efficiency and toxicity. Patients with colorectal cancer are likely to receive one or several lines of chemotherapy with variable efficacy and to experience some related side effects. It is therefore critical to tailor the best therapeutic arsenal to improve treatments efficacy meanwhile avoiding adverse reactions susceptible to lead to treatment disruption as much as possible. The purpose of pharmacogenetics studies is to specifically investigate for each drug the implicated metabolic pathways and their potential individual variations related to genomic or somatic mutations. This research aims at identifying both prognostic and predictive biomarkers that will help for the best treatment selection. In CRC, one important issue remains to evaluate the survival benefit of adjuvant chemotherapy administration in patients with stage II and III CRC. In this setting, the survival advantage given by adjuvant 5-fluoruracil-infusion (with or without oxaliplatin) has been shown for patients with stage III CRC but is still undetermined for patients with stage II CRC. By definition somatic mutations can be found in tumor cells genome and have been related with response to chemotherapeutic agents. In addition, several reports suggested the important role of inherited variations (constitutional or germ line) for drug response and side effects prediction

Style APA, Harvard, Vancouver, ISO itp.

Muhammad, Karim B. "Gastrin and colorectal cancer". Thesis, University of Newcastle upon Tyne, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.401281.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Gryfe, Robert. "Colorectal cancer microsatellite instability". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ59033.pdf.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Bridges, James. "Necrosis in colorectal cancer /". Leeds : University of Leeds, School of Computer Studies, 2008. http://www.comp.leeds.ac.uk/fyproj/reports/0708/Bridges.pdf.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Briggs, Christopher David. "ZEB1 in colorectal cancer". Thesis, University of Leicester, 2012. http://hdl.handle.net/2381/10917.

Pełny tekst źródła

Streszczenie:

Colorectal cancer (CRC) is one of the commonest malignancies in the United Kingdom and tumour cell invasion and metastasis is the main cause of death. The transcriptional repressor ZEB1 has been shown to be expressed in several epithelial malignancies and embryonic epithelial-mesenchymal transitions (EMT). The understanding of cellular signalling cascades should allow the discovery of novel targets for potential future therapeutic manipulation in the treatment of colorectal cancer and other malignancies. Here, in order to further investigate the role of ZEB1 in CRC, in vitro investigations and immunohistochemical analysis of 101 colorectal cancers and their matched lymph node and liver metastases are performed. The Wnt-Inducible Signalling Proteins and Plakophilin-3 are also investigated for their relationship with ZEB1 signalling. ZEB1 is expressed in tumour cell lines with mesenchymal characteristics and over-expression in an epithelial-phenotype cancer cell line causes down-regulation of epithelial markers such as E-cadherin and Plakophilin-3. Knockdown of ZEB1 in mesenchymal cell lines caused up-regulation of PKP-3 expression. In vitro attempts at manipulation of WISP expression were unsuccessful. In CRC tumours ZEB1 was noted to be up-regulated at the tumour invasive front, with concomitant loss of Plakophilin-3 expression. However expression of these markers did not correlate with disease stage or survival on multivariable analysis. Increased WISP-1 nuclear and cytoplasmic expression were noted at the tumour invasive front and correlated with disease stage and several pathological factors on univariable analysis. Increased nuclear WISP-1 expression at the invasive front correlated with survival on uni- and multivariable analysis. This study demonstrates that ZEB1, Plakophilin-3 and WISP-1 are expressed in CRC and may be involved in tumour cell invasion and dissemination at the invasive front. Expression of nuclear WISP-1 is an independent predictor of poor survival and is worthy of further investigation as a target of future therapeutic intervention.

Style APA, Harvard, Vancouver, ISO itp.

陳安安 i On-on Annie Chan. "Methylation in colorectal cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B25256312.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Webley, Katherine Mary. "p53 in colorectal cancer". Thesis, University of Sheffield, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.286842.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Jones, David John. "Prognosis in colorectal cancer". Thesis, University of Liverpool, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.235501.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Ford, Mauntell. "Obesity Induced Colorectal Cancer". The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1365865780.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Książki na temat "Colorectal cancer"

Powell, Steven M. Colorectal Cancer. New Jersey: Humana Press, 2000. http://dx.doi.org/10.1385/1592590845.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Service, Gastrointestinal Oncology. COLORECTAL CANCER. Abingdon, UK: Taylor & Francis, 1988. http://dx.doi.org/10.4324/9780203213650.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Scholefield, John H., i Cathy Eng, red. Colorectal Cancer. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118337929.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Hardcastle, Jack Donald, red. Colorectal Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78225-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Brown, Gina, red. Colorectal Cancer. Cambridge: Cambridge University Press, 2007. http://dx.doi.org/10.1017/cbo9780511902468.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Seitz, Helmut Karl, Ulrich A. Simanowski i Nicholas A. Wright, red. Colorectal Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-85930-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Ponz de Leon, Maurizio. Colorectal Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-56008-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Markman, Maurie, i Leonard B. Saltz, red. Colorectal Cancer. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-215-1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Saltz, Leonard B., red. Colorectal Cancer. Totowa, NJ: Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Beaulieu, Jean-François, red. Colorectal Cancer. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7765-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Części książek na temat "Colorectal cancer"

Cherny, Nathan I. "Cancer Pain Syndromes in Colorectal and Anal Cancers". W Colorectal Cancer, 637–57. Totowa, NJ: Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2_35.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Hill, M. J. "Colorectal Bacteria in Colorectal Carcinogenesis". W Colorectal Cancer, 160–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-85930-4_10.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Russell, Travis C. "Colorectal Cancer". W Family Medicine, 1199–210. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-04414-9_99.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Yu, Yao, Mekhail Anwar i Hans T. Chung. "Colorectal Cancer". W Handbook of Evidence-Based Radiation Oncology, 491–514. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-62642-0_22.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Granov, Anatoliy, Leonid Tiutin i Thomas Schwarz. "Colorectal Cancer". W Positron Emission Tomography, 103–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-21120-1_8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Adiga, Giridhar U., i Janice P. Dutcher. "Colorectal Cancer". W Geriatric Gastroenterology, 587–95. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-1623-5_63.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Calvo, Felipe A., Ignacio Azinovic, Fernando Pardo, José L. Hernández i Javier Alvarez-Cienfuegos. "Colorectal Cancer". W Intraoperative Radiotherapy, 65–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5_9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Shibata, Hirofumi, Ukihide Tateishi i Tomio Inoue. "Colorectal Cancer". W Clinical PET and PET/CT, 273–79. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0802-5_24.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Wolner, Kathleen. "Colorectal Cancer". W Encyclopedia of Women’s Health, 289–91. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-0-306-48113-0_97.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Brotzman, Gregory L., i Russell G. Robertson. "Colorectal Cancer". W Family Medicine, 795–800. New York, NY: Springer New York, 1998. http://dx.doi.org/10.1007/978-1-4757-2947-4_92.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Colorectal cancer"

Sudakov, A. I., E. P. Kulikov, S. A. Mertsalov, A. A. Nikiforov i V. A. Grigorenko. "GENETIC POLYMORPHISM AND COLORECTAL CANCER". W NOVEL TECHNOLOGIES IN MEDICINE, BIOLOGY, PHARMACOLOGY AND ECOLOGY. Institute of information technology, 2022. http://dx.doi.org/10.47501/978-5-6044060-2-1.105-109.

Pełny tekst źródła

Streszczenie:

The article analyzes the relationship of polymorphism of a number of genes with some features of colorectal cancer, such as the aggressiveness of its course and development of the disease, the effectiveness of preoperative chemoradiotherapy. The data obtained can be used to deter-mine individual tactics for treating patients.

Style APA, Harvard, Vancouver, ISO itp.

Nagi, Karim, Ishita Gupta, Hamda A. Al-Thawadi, Ayesha Jabeen, Mohammed I. Malk, Semir Vranic i Ala-Eddin Al-Moustafa. "Comparison of Co-Presence of Epstein-Barr Virus and High-Risk Human Papillomaviruses in Colorectal Cancers in the Middle East Region". W Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0121.

Pełny tekst źródła

Streszczenie:

Background: Several studies have shown the presence of onco viral DNA in colorectal tumor tissues. Viral infection by onco-viruses such as Human papillomaviruses (HPVs) and Epstein–Barr virus (EBV) are well-known to be involved in the onset and/or progression of numerous human carcinomas. Methods: We explored the co-presence of high-risk HPVs and EBV in a cohort of colorectal cancer samples from Lebanon (94) and Syria (102) by PCR, immunohistochemistry and tissue microarray. Results: The results of the study point out that 54% of colorectal cancer cases in Syria are positive for high-risk HPVs, while 30% of the cases in Lebanon are positive for these viruses; the most frequent high-risk HPV types in these populations are 16, 18, 31, 33 and 35. Analysis of LMP1 showed similar results in both populations; 36% of Syrian and 31% of Lebanese samples. Additionally, we report that EBV and high-risk HPVs are co-present in these samples. In Syrian samples, EBV and HPVs are co-present in 16% of the population, however, in the Lebanese samples, 20% of the cases are positive for both EBV and HPVs; their co-presence is associated with high/intermediate grade invasive carcinomas. Conclusion: These data suggest that EBV and high-risk HPVs are co-present in human colorectal cancers where they can cooperate in the progression of these cancers. Nevertheless, further studies are needed to elucidate the role of those oncoviruses in the development of human colorectal carcinomas.

Style APA, Harvard, Vancouver, ISO itp.

Sherman, Recinda, Kevin Henry i David Lee. "Addressing colorectal cancer disparities". W the First ACM SIGSPATIAL International Workshop. New York, New York, USA: ACM Press, 2012. http://dx.doi.org/10.1145/2452516.2452520.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Carethers, John M. "Abstract IA02: Colorectal cancer". W Abstracts: Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2017; Atlanta, GA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7755.disp17-ia02.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Marques, Flavia Araújo Marques, i Matheus Moreira. "EPIGENETICS IN COLORECTAL CANCER". W Congresso Online de Atualização em Oncologia. Congresse.me, 2023. http://dx.doi.org/10.54265/mobq8354.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Betel, Doron, Heather Yeo, Rhonda Yantiss, Xi E. Zheng, Jonathan S. Abelson i Manish A. Shah. "Abstract 274: Early-onset colorectal cancer is distinct from traditional colorectal cancer". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-274.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Abubekerov, S. K., A. V. Kornilov i I. A. Tyurina. "ASSESSMENT OF THE EFFECT OF THE MICROBIOME ON THE DEVELOPMENT OF COLORECTAL CANCER AFTER SURGERY ON THE GASTROINTESTINAL TRACT". W Scientific research of the SCO countries: synergy and integration. Crossref, 2024. http://dx.doi.org/10.34660/inf.2024.38.71.003.

Pełny tekst źródła

Streszczenie:

We studied the influence of the microbiome on the development of colorectal cancer (CRC) after surgical interventions on the gastrointestinal tract (GIT) (appendectomy, cholecystectomy, polypectomy). 381 patients were analyzed; variables such as CRC mutational activity (KRAS, BRAF, MSI, NRAS, HER2) were included in the study. The analysis showed a high frequency of BRAF mutations in patients with a previous appendectomy, 4.8 times compared to the control group. We associate the obtained data with the influence of Fusobacterium nucleatum on the development of colorectal cancer, the role of which is described in modern literature. Cholecystectomy and polypectomy did not have a sufficient effect on the development of colorectal cancer.

Style APA, Harvard, Vancouver, ISO itp.

Xicola, Rosa M., Molly Gagnon, Jacob Shaw, Gary Rodriguez, Cenk Pusatcioglu, Julia Clark, Rawson James i in. "Abstract 3597: The Chicago Colorectal Cancer Consortium (CCCC) experience: Understanding colorectal cancer disparities". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3597.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Ternes, Dominik, Martine Schmitz, Léa Grandmougin, Mina Tsenkova, Eric Koncina, Aurélien Ginolhac, Jessica Karta i in. "Abstract A09: Understanding the role of colorectal cancer-associated microbes in colorectal cancer". W Abstracts: AACR Special Conference on the Microbiome, Viruses, and Cancer; February 21-24, 2020; Orlando, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.mvc2020-a09.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Alfonso-Garcia, Alba, Lisanne Kraft, Xiagnan Zhou, Julien Bec, Laura Marcu, Dongguang Wei, Shiro Urayama i Asha Cogdill. "Colorectal Polyp Assessment with Label-Free Fluorescence Lifetime Imaging". W Clinical and Translational Biophotonics. Washington, D.C.: Optica Publishing Group, 2024. http://dx.doi.org/10.1364/translational.2024.tm3b.2.

Pełny tekst źródła

Streszczenie:

Standard colonoscopy fails to distinguish malignant from benign colorectal tissue in real-time. Colonoscopy-compatible label-free fluorescence lifetime imaging (FLIm) in 15 patients identified malignant lesions, encouraging a non-invasive screening method for colorectal cancer.

Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Colorectal cancer"

Ellington, Taylor. Colorectal Cancer Incidence, United States—2003−2019. United States Cancer Statistics (USCS), marzec 2023. http://dx.doi.org/10.15620/cdc:126261.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Chang, Min Cheol, Yoo Jin Choo i Sohyun Kim. Effect of Prehabilitation for Patients with Frailty Undergoing Colorectal Cancer Surgery: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, listopad 2022. http://dx.doi.org/10.37766/inplasy2022.11.0105.

Pełny tekst źródła

Streszczenie:

Review question / Objective: We performed a meta-analysis to assess the impact of prehabilitation before colorectal surgery on functional outcome and postoperative complications in patients with frailty. Condition being studied: Colorectal cancer is a common disease in the elderly, and over 65 years of age accounts for more than 50% of all patients with colorectal cancer. The patients with colorectal cancer surgery showed 8.7% major morbidity and mortality and 31.6% minor complications. The high complication rate of patients with colorectal surgery is related to the fact that there are many elderly patients. Frailty is common in elderly patients, and the frailty is associated with adverse perioperative outcomes. The frail patients with colorectal surgery showed worse postoperative morbidity, mortality and prolonged length of hospital stay. Although the frailty results from irresistible aging-associated decline in reserve and function across multiple physiologic systems, several attempts have been conducted to improve frailty in patients with colorectal cancer surgery and consequently improve the postoperative outcomes. Prehabilitation was one of these attempts for improving physical activity and postoperative outcomes on patients with frailty undergoing colorectal cancer surgery. So far, several studies conducted clinical trials for determining whether prehabilitation has positive effect on improving postoperative outcomes in patients with frailty undergoing colorectal surgery. However, the results of these previous studies are controversial.

Style APA, Harvard, Vancouver, ISO itp.

Ying, Hongan, Jinfan Shao, Xijuan Xu, Wenfeng Yu i Weiwen Hong. Perineural Invasion is an Indication of Adjuvant Chemotherapy in Node Negative Colorectal cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, grudzień 2021. http://dx.doi.org/10.37766/inplasy2021.12.0103.

Pełny tekst źródła

Streszczenie:

Review question / Objective: Perineural invasion (PNI) is a possible route for metastatic spread in various cancer types, including colorectal cancer (CRC). PNI is linked to poor prognosis. For patients with lymph node positive colorectal cancer, a number of large-scale RCT studies have confirmed that they can benefit from chemotherapy, but there are still many controversies about whether colorectal patients with negative lymph nodes need adjuvant chemotherapy. At present, there is a general consensus that patients with stage II colorectal cancer who have risk factors such as PNI+ need chemotherapy. However, there are many recent literatures that show that patients with stage II colorectal cancer with nerve invasion risk factors can not prolong the OS and DFS of patients. At the same time, chemotherapy increases the toxicity, economic and mental burden of patients. Therefore, we hope to write this review to summarize the current research findings and provide some clinical guidance on whether patients with lymph node negative colon cancer who have perineural invasion should receive chemotherapy. Condition being studied: Patients with high-risk such as PNI+ stage II colon cancer (CC) are recommended to undergo adjuvant chemotherapy (ACT). However, whether such patients can benefit from ACT remains unclear. And recently studies shown that, ACT had no significant benefit among patients with PNI.

Style APA, Harvard, Vancouver, ISO itp.

CHEN, Danfeng, Jianquan CHEN, Xutong ZHENG, Zhuzhu QIN, Simin HUANG i Chenju ZHAN. Stigma in colorectal cancer patients with colostomy, China: A systematic review and meta-analysis of current status and associated psychological factors. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2023. http://dx.doi.org/10.37766/inplasy2023.2.0073.

Pełny tekst źródła

Streszczenie:

Review question / Objective: To analyze the current stigma and related factors of colorectal cancer stoma patients in China using Meta-analysis. To analyze the current stigma and related factors of colorectal cancer stoma patients in China using Meta-analysis.: (1) The study design was: an observational study (cohort study, case-control study, cross-sectional study) (2) The study population was post-stoma patients with colorectal cancer in China (3) The study index needed to contain at least one scale related to the stigma that was tested for reliability (4) The outcome index needed to contain the level of stigma (x± s) or at least one psychological variable related to stigma after colorectal cancer stoma and report the correlation coefficient.

Style APA, Harvard, Vancouver, ISO itp.

Chang, Min Cheol, Yoo Jin Choo i Sohyun Kim. Effect of Prehabilitation in Colorectal Cancer Surgery: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, październik 2022. http://dx.doi.org/10.37766/inplasy2022.10.0015.

Pełny tekst źródła

Streszczenie:

Review question / Objective: Colorectal cancer increases with age, and elderly patients are associated with a poorer prognosis after colorectal surgery. Since comorbidity and frailty are associated with clinical outcomes, several strategies are introduced to improve clinical outcomes according to correct those.Despite efforts to improve the clinical outcome after surgery, patients with colorectal surgery still frequently experience complications. While Enhanced Recovery After Surgery has standardized principals, prehabilitation program varied among studies. The prehabilitation program according to the study showed differences in patient selection criteria, exercise, nutritional support, and methods of the outcome measurement. Therefore, various results have been reported regarding the effect of prehabilitation. The effectiveness of prehabilitation is still controversial. The aim of this study was to confirm the updated overall spectrum and measure the effect of prehabilitation in patients with colorectal cancer surgery.

Style APA, Harvard, Vancouver, ISO itp.

N Chui, Juanita, William A Ziaziaris, Ali Mohtashami, Christopher SH Lim, Nazim Bhimani i Thomas J Hugh. Biliary Metastases from Colon Cancer: A Rare Differential Diagnosis for Obstructive Jaundice. Science Repository, grudzień 2022. http://dx.doi.org/10.31487/j.ajscr.2022.03.03.

Pełny tekst źródła

Streszczenie:

Metastatic infiltration of the biliary tree is a rare manifestation of colorectal cancer. Currently, there is limited evidence to inform the management of such cases and the prognosis is poor. Herein, we report a case of biliary colorectal metastases with extensive multifocal involvement and discuss the challenges of the diagnosis and treatment.

Style APA, Harvard, Vancouver, ISO itp.

Yelena, Gorina, i Elgaddal Nazik. Patterns of Mammography, Pap Smear, and Colorectal Cancer Screening Services Among Women Aged 45 and Over. National Center for Health Statistics, czerwiec 2021. http://dx.doi.org/10.15620/cdc:105533.

Pełny tekst źródła

Streszczenie:

This study examines and compares sociodemographic, health status, and health behavior patterns of screening for breast cancer, cervical cancer, and colorectal cancer among women aged 45 and over in the United States.

Style APA, Harvard, Vancouver, ISO itp.

Roper, Jatin. The Role of Akt Isoforms in Colorectal Cancer. Fort Belvoir, VA: Defense Technical Information Center, lipiec 2014. http://dx.doi.org/10.21236/ada613186.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Billingsley, Megan, Tiameria Ford, Mikayla Vican i Diana Dedmon. Increasing Colorectal Cancer Screening Adherence: A Scoping Review. University of Tennessee Health Science Center, kwiecień 2022. http://dx.doi.org/10.21007/con.dnp.2022.0033.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Rawl, Susan, Susan Perkins, Yan Tong, Connie Krier, Hala Fatima, Peter Schwartz, Thomas Imperiale_ Imperiale i in. Comparing Three Ways to Increase Colorectal Cancer Screening. Patient-Centered Outcomes Research Institute® (PCORI), czerwiec 2022. http://dx.doi.org/10.25302/06.2022.ihs.150731333.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!